THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

October 02, 2024
SK Innovation develops low-cost membrane for carbon capture

SK Innovation, with its subsidiary SK IE Technology and researchers from Yonsei University, has developed a next-generation technology designed to capture carbon emissions more efficiently and at a lower cost. This breakthrough could have significant implications for the biggest carbon-emitting ind...
September 30, 2024
Daewoong's new drug patents reach 88% of total

South Korean drug maker Daewoong Pharmaceutical said Monday that more than 88 percent of its patents registered over the past five years in the country have been for new drugs, reflecting the firm’s efforts to enhance its competitiveness in both domestic and global markets through the development ...
September 20, 2024
Yuhan, Janssen halt next-gen cancer drug collaboration

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted anticancer drug, citing the strong efficacy of its existing treatment, which has reduced the need for further development. According to...
September 19, 2024
Daewoong to lead homegrown hyperlipidemia therapy

According to the group, most raw materials for hyperlipidemia drugs produced in Korea are currently manufactured using a "batch process" method, which operates each process separately. In contrast, Daewoong's "continuous process" ensures consistent quality by allowing raw materials to be input in a...
September 13, 2024
Celltrion secures contract to supply Herzuma to Brazil for 5th year

South Korean biosimilar giant Celltrion will continue to supply trastuzumab biosimilar Herzuma to Brazil, the company announced Friday. The company won the bid to supply a trastuzumab biosimilar to the Brazilian Federal Government for the fifth consecutive year. Under the contract, Celltrion will...
September 11, 2024
Celltrion Remsima SC hits record share in Australia in Q1

Celltrion’s Remsima SC, the world’s only subcutaneous formulation of infliximab, has reached a record market share in Australia, the Korean biosimilar giant announced Wednesday. According to data from pharmaceutical market research firm IQVIA, Remsima SC achieved a 20 percent market share for th...
September 04, 2024
Celltrion's Stelara biosimilar receives approval in UK

South Korean biosimilar giant Celltrion announced Wednesday that Steqeyma, the company's biosimilar referencing Stelara, has been approved in the UK, following earlier approvals by Korea, Canada and the European Commission this year. According to the company, Steqeyma has received approval from th...
August 26, 2024
GI Innovation partners with MSD for new cancer drug combination

South Korean biotech company GI Innovation announced Monday a new partnership with Merck Sharp & Dohme, a subsidiary of pharmaceutical company Merck & Co., to test its drug GI-102 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) for treating patients with immunotherapy-resistan...
August 26, 2024
Celltrion gets European approval for Stelara biosimilar

South Korean biopharmaceutical firm Celltrion announced Monday that it has received the European Commission’s final approval for Steqeyma, a Stelara (ustekinumab) biosimilar used to treat various autoimmune conditions. Steqeyma, or CT-P43, has been approved for use in all indications of reference...
August 19, 2024
Celltrion eyes top 5 drug maker by 2030

South Korean biopharmaceutical firm Celltrion Pharm unveiled Monday a new vision to become one of South Korea’s top five pharmaceutical companies by 2023. Under Vision 2030, Celltrion Pharm said the company aims to make a quantum leap by enhancing its core business strengths and implementing diff...
August 19, 2024
Daewoong’s botulinum toxin debuts in Australia

Daewoong Pharmaceutical, South Korea’s leading drug maker, announced Monday the company officially launched its botulinum toxin, dubbed Nuceiva, in Australia in partnership with a Nasdaq-listed US company Evolus. Oceania is the fifth continent Daewoo Pharmaceutical has entered, after North Americ...
August 16, 2024
Celltrion scraps merger plan after investor backlash

Celltrion Group on Friday ditched its planned merger of the two units Celltrion and Celltrion Pharm after months of fierce resistance from shareholders. The two companies announced that they would focus on their core operations and work on creating synergy within their respective firms. The decisi...
August 16, 2024
NeuroBo Pharmaceuticals completes patient enrollment for phase 1 trial for antiobesity drug

NeuroBo Pharmaceuticals, the Nasdaq-listed biotech firm affiliated with South Korean drug maker DongA ST, announced Wednesday the company has completed patient enrollment for the first part of the phase 1 clinical trial for its antiobesity drug, dubbed DA-1726. DA-1726, designed to induce weight l...
August 06, 2024
Daewoong debuts Fexuclue in Latin America

South Korean drug maker Daewoong Pharmaceutical said Tuesday that it launched its gastroesophageal reflux disease, or GERD, treatment Fexuclue in Mexico, Ecuador and Chile. According to pharmaceutical market research firm IQVIA, the market for antiulcer drugs in these three countries was valued at...
July 24, 2024
LG Chem’s US partner starts phase 2 trial on rare obesity drug

LG Chem announced on Wednesday that Rhythm Pharmaceuticals, which had acquired the global license for LB54640 -- a new oral drug for a rare form of obesity developed by LG Chem -- has begun giving doses to the first participants in a phase 2 clinical trial. For the phase 2 trial, Rhythm Pharmaceut...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099